ArticleJournal of virology2013
Design requirements for interfering particles to maintain coadaptive stability with HIV-1.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Coevolutionary dynamics of viruses and their defective interfering particles.PLoS computational biology · 2026Article
- Superinfection promotes replication and diversification of defective HIV-1 proviruses in people with non-suppressible viraemia.Nature microbiology · 2025Article
- Coevolutionary dynamics of viruses and their defective interfering particles.bioRxiv : the preprint server for biology · 2025Article
- Quantifying the Inhibitory Efficacy of HIV-1 Therapeutic Interfering Particles at a Single CD4 T-Cell Resolution.Viruses · 2025Article
- Exploiting social traits for clinical applications in bacteria and viruses.npj antimicrobials and resistance · 2025Review
- Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates.Science (New York, N.Y.) · 2024Article
- Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies.Communications medicine · 2023Review
- Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study.Scientific reports · 2021Article
- Article
- Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome.PLoS pathogens · 2021Article
- An evolution-based high-fidelity method of epistasis measurement: Theory and application to influenza.PLoS pathogens · 2021Article
- The evolutionary origin of the universal distribution of mutation fitness effect.PLoS computational biology · 2021Article
- Article
- Defective viral genomes are key drivers of the virus-host interaction.Nature microbiology · 2019Review
- A Novel Type of Influenza A Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome.Journal of virology · 2019Article
- Stable Transcriptional Repression and Parasitism of HIV-1.Molecular therapy. Nucleic acids · 2018Article
- Antigenic evolution of viruses in host populations.PLoS pathogens · 2018Article
- The evolutionary ecology of molecular replicators.Royal Society open science · 2016Article
- Exploiting Genetic Interference for Antiviral Therapy.PLoS genetics · 2016Review
- Conflicting Selection Pressures Will Constrain Viral Escape from Interfering Particles: Principles for Designing Resistance-Proof Antivirals.PLoS computational biology · 2016Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Defective interfering particles (DIPs) are viral deletion mutants lacking essential transacting or packaging elements and must be complemented by wild-type virus to propagate. DIPs transmit through human populations, replicating at the expense of the wild-type virus and acting as molecular parasites of viruses. Consequently, engineered DIPs have been proposed as therapies for a number of diseases, including human immunodeficiency virus (HIV). However, it is not clear if DIP-based therapies would face evolutionary blocks given the high mutation rates and high within-host diversity of lentiviruses. Divergent evolution of HIV and DIPs appears likely since natural DIPs have not been detected for lentiviruses, despite extensive sequencing of HIVs and simian immunodeficiency viruses (SIVs). Here, we tested if the apparent lack of lentiviral DIPs is due to natural selection and analyzed which molecular characteristics a DIP or DIP-based therapy would need to maintain coadaptive stability with HIV-1. Using a well-established mathematical model of HIV-1 in a host extended to include its replication in a single cell and interference from DIP, we calculated evolutionary selection coefficients. The analysis predicts that interference by codimerization between DIPs and HIV-1 genomes is evolutionarily unstable, indicating that recombination between DIPs and HIV-1 would be selected against. In contrast, DIPs that interfere via competition for capsids have the potential to be evolutionarily stable if the capsid-to-genome production ratio of HIV-1 is >1. Thus, HIV-1 variants that attempt to "starve" DIPs to escape interference would be selected against. In summary, the analysis suggests specific experimental measurements that could address the apparent lack of naturally occurring lentiviral DIPs and specifies how therapeutic approaches based on engineered DIPs could be evolutionarily robust and avoid recombination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.